Hyderabad: A biotechnology startup, incubated at the ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH), announced on Monday that a human umbilical cord (UC) tissue is harvested and based on clinically processed mesenchymal stem cells (MSCs) is. for COVID-19 patients.
Transcell Oncologics has developed its own cell-based platform technology, HEMATO UC-MSCs, with anti-cytokine storm properties, anti-inflammatory properties and repair capabilities.
The treatment is associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 ‘cytokine storm’, with the patient’s survival and recovery time significantly improved.
The research recommends that HEMATO UC-MSCs be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, with 72 hours COVID-19 patients ”.
Subadra Dravida, founder and CEO of Transcell, said: “The benefit of therapy is this new way of healing COVID-19 patients in real time to STORE it and NOT to treat the symptoms alone. Also if HEMATO UC-MSCs are administered as the first line of treatment, followed by concomitant steps to alleviate the concomitant symptoms in a traditional way, COVID-19 deaths can be avoided ”.
HEMATO UC-MSCs can be delivered to India within 48 hours and are specially treated within 72 hours for storage under 2-8 degree Celsius refrigeration conditions.
The efficacy of this MSC-based technology is limited by the Cell Transplant Center, Miami Miller School of Medicine, Jackson Health System, Department of Public Health Sciences, USA, at COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).
It issued a detailed research paper on a randomized controlled trial and confirmed the laboratory findings of Transcell Oncologics.
Source: The Siasat Daily